Relationships between genetic alterations, such as co-occurrence or mutual exclusivity, are often observed in cancer, where their understanding may provide new insights into etiology and clinical management. In this study, we combined statistical analyses and computational modelling to explain patterns of genetic alterations seen in 178 patients with bladder tumours (either muscle-invasive or non-muscleinvasive). A statistical analysis on frequently altered genes identified pair associations including co-occurrence or mutual exclusivity. Focusing on genetic alterations of protein-coding genes involved in growth factor receptor signalling, cell cycle and apoptosis entry, we complemented this analysis with a literature search to focus on nine pairs of genetic alterations of our dataset, with subsequent verification in three other datasets available publically. To understand the reasons and contexts of these patterns of associations while accounting for the dynamics of associated signalling pathways, we built a logical model. This model was validated first on published mutant mice data, then used to study patterns and to draw conclusions on counter-intuitive observations, allowing one to formulate predictions about conditions where combining genetic alterations benefits tumorigenesis. For example, while 
Abstract
Relationships between genetic alterations, such as co-occurrence or mutual exclusivity, are often observed in cancer, where their understanding may provide new insights into etiology and clinical management. In this study, we combined statistical analyses and computational modelling to explain patterns of genetic alterations seen in 178 patients with bladder tumours (either muscle-invasive or non-muscleinvasive). A statistical analysis on frequently altered genes identified pair associations including co-occurrence or mutual exclusivity. Focusing on genetic alterations of protein-coding genes involved in growth factor receptor signalling, cell cycle and apoptosis entry, we complemented this analysis with a literature search to focus on nine pairs of genetic alterations of our dataset, with subsequent verification in three other datasets available publically. To understand the reasons and contexts of these patterns of associations while accounting for the dynamics of associated signalling pathways, we built a logical model. This model was validated first on published mutant mice data, then used to study patterns and to draw conclusions on counter-intuitive observations, allowing one to formulate predictions about conditions where combining genetic alterations benefits tumorigenesis. For example, while CDKN2A homozygous deletions occur in a context of FGFR3 activating mutations, our model suggests that additional PIK3CA mutation or p21CIP deletion would greatly favour invasiveness. Further, the model sheds light on the temporal orders of gene alterations, for example, showing how mutual exclusivity of FGFR3 and TP53 mutations is interpretable if FGFR3 is mutated first. Overall, our work shows how to predict combinations of the major gene alterations leading to invasiveness through two main progression pathways in bladder cancer.
Major Findings: Statistical analyses of bladder cancer genetic data reveal cooccurring or mutually exclusive genetic alterations for genes frequently altered in this cancer. The interactions between these genes are organized into an influence network based on literature analysis. We find that the sole network topology is not sufficient to explain some of the nine identified associations. To assess these associations while accounting for the dynamics of associated signalling pathways, we have developed a logical model. For the identified patterns, our model sheds light on aberrant activation of signalling pathways and provides predictions.
Quick Guide to Equations and Assumptions

Influence network
In an influence network, details of synthesis, degradation, phosphorylation, acetylation or ubiquitination are abstracted into binary relations. Nodes (biochemical species or phenomena) are connected through directed, signed edges (denoting regulatory interactions). For instance, RB1 is known to sequester E2F1 by forming an inactive complex. This reaction is interpreted as RB1 inhibiting E2F1. Another example is the phenomenological node Proliferation, which is activated by both CyclinE1 and CyclinA. Throughout the article, when referring to the genes, their names will be italicized (e.g., CCND1), and the nodes of the network will be written in standard format (e.g., CyclinD1).
amplification of a gene locus) justifies a discrete modelling approach. Each node of the network is associated with a discrete variable representing its qualitative functional level. A Boolean variable is often sufficient to convey the role of the corresponding node: species are either active (ON) or inactive (OFF), thus able, or not, to act upon their targets. In some cases, more than two levels are needed to convey distinct functional roles. For instance, E2F1 mediates the transcription of cell cycle genes, but when overexpressed, it activates genes of the apoptotic pathway. To distinguish between these two situations, E2F1 is associated with a multivalued variable (values 0, 1 or 2).
The variables describe the current node states, which evolve depending on logical rules. More precisely, the target level of each node is defined by a set of logical statements on the levels of the regulators of that node, using logical connectors (denoted ! for NOT, & for AND, and | for OR).
For example, the Boolean variable associated with Proliferation evolves as follows:
Statement (1) in a CHEK1_2-dependent manner in the absence of RB1 and in the presence of RAS.
For any other situation, the target value of E2F3 is 0.
Given a state of the model, i.e., a vector of all node levels, some of the nodes may be called to update their levels as prescribed by their logical rules. Because we have no information about the velocities of these changes, we opt for the asynchronous update that defines as many successor states as the number of updated nodes. The resulting discrete dynamics is non-deterministic (a state may have several successors) and covers all potential behaviours of the network, compatible with logical rules.
The attractors of the logical model refer to long-term behaviours (sets of states in which the dynamics is trapped). These attractors are stable states (all nodes are stable), or complex attractors (some nodes display oscillations).
In this modelling framework, perturbations of gene activity are defined as follows:
variable associated with the perturbed node is constrained, overriding its logical rule.
A gain of function, amplification or overexpression is specified by maintaining a variable at 1 (or at its maximal level in the case of a multivalued variable), and is denoted by the broad term "overexpression", whereas a loss-of-function or deletion is defined by maintaining a variable at 0 (denoted KO).
Assessing phenotypes
In order to interpret the model results, we associate observed biological phenotypes with attractors of the discrete model. These attractors correspond to phenotypes specified by the states of the output nodes: Proliferation, Apoptosis (E2F1 or TP53-dependent) and Growth_arrest. From a given set of initial conditions, the possible fates of a cell are assessed in terms of the phenotypes that can be reached from these conditions and the probabilities associated to those phenotypes. Associating a phenotype with a stable state is straightforward, whereas a cyclic attractor may include oscillations between several phenotypes, when the cell decision cannot be made. The probability of a phenotype is estimated as the proportion of trajectories leading to any attractor matching this phenotype. Input components are maintained constant (corresponding to external signals). While some input values lead to multistability (several possible phenotypes), some others drive the cell, deterministically, to a unique phenotype; e.g., in most cases, the sole Apoptosis is possible when DNA_damage is ON.
Introduction
Accumulated data show specific patterns of genetic and epigenetic changes associated with each cancer type. These patterns include particular sets of altered genes, types (mutations, amplifications, losses) and relationships (mutual exclusivity or co-occurrence) between alterations. The underlying molecular network should, at least partly, explain such observations. So far, these patterns have been explained in terms of linear pathways: co-occurring mutations tend to target genes in parallel signalling pathways whereas mutual exclusive alterations may implicate genes involved either in a common pathway, or in different progression pathways, i.e. in different tumour types (1) (2) (3) (4) (5) . Mutual exclusivity could also involve genes that are synthetically lethal (6) . These explanations are only hand waving arguments, though.
Indeed, the static network structure-based analysis of these patterns has its limitations. Pathways involved in tumorigenesis are complex and interconnected, and it is therefore difficult to define the borders of a signalling pathway, and the notion of parallel or common pathways. Mathematical modelling may help to go further in these interpretations.
Here, we show how dynamical modelling can relate complex networks with observable biological data (genomic alterations, mutations). Computational modelling allows to integrate and validate current knowledge about molecular mechanisms underlying cellular decisions. It supports mechanistic understanding and helps to formulate predictions when the network complexity defies intuition. This is particularly true when dealing with diseases such as cancer, which involve the deregulation of multiple and intricate pathways (7) . Numbers of models have already proved useful in elucidating questions related to cancer biology (8) (9) (10) (11) (12) (13) Bladder cancer is frequent in Europe and North America where it represents the fourth cancer in men and the ninth in women in terms of incidence (14) . The high recurrence rate makes bladder cancer one of the most costly cancers to treat. Many observations of the patterns of genetic changes identified in bladder cancer studies remain unexplained or only partially explained in terms of underlying molecular mechanisms (15, 16) . Bladder tumours progress along two main pathways: Ta and CIS (Carcinoma in situ) pathways (17, 18) . About 50% of diagnosed bladder carcinomas are Ta tumours, generally of low grade; 20% are T1 tumours and 30% are muscle-invasive tumours (T2-4). CIS consists of flat, high-grade lesions, rarely found in absence of other bladder tumours. Ta tumours often recur and progress rarely (5 to 10% of cases) but unpredictably to T1 and then to muscle-invasive tumours (T2-4), whereas CIS often progress to T1 and then to muscle-invasive tumours in circa 50% of the cases. It is believed that about 80% of muscle-invasive tumours develop through the CIS pathway. In bladder cancer, as in many cancer types, an important fraction of genetic alterations concerns genes coding for growth signalling factors and for G1/S regulators. Activating mutations of the fibroblast growth factor receptor 3 (FGFR3) gene are associated with the Ta pathway with a high frequency, but are rarely found in the CIS pathway (17) . Beside FGFR3, mutated in about 45% of tumours (19) , common genes recurrently genetically altered include other oncogenes like the small GTPases HRAS (9% of cases) and KRAS (4% of cases), PIK3CA (subunit of the PI3 kinase, 18% of cases), as well as tumour suppressors such CDKN2A (16% of cases) and RB1 (20% of cases) (52). Mutations affecting oncogenes are recurrent point mutations, whereas CDKN2A is mostly affected by losses involving the whole gene (20) . RB1 is targeted by both point mutations and deletions (21) . Our goal is to understand how genetic alterations (mutations, homozygous deletions or amplifications) combine to promote cancer tumorigenesis. More precisely, we aim to explore patterns (mutual exclusivity or co-occurrence), focusing on components often altered in bladder cancer and involved in growth factor signalling, cell cycle entry and triggering of apoptosis in response to DNA damage with the focus on the E2F pathway. It has been shown recently that the E2F pathway is not only involved in the control of proliferation but also in invasion and metastasis (22) (23) (24) , justifying the study of this pathway to explore invasiveness in bladder tumours.
This study combines literature search, statistical analysis of relevant datasets and logical modelling of the related signalling network. Using an initial dataset of 178 tumours (CIT series) and three public datasets, statistical tests on pairs of alterations identify a list of co-occurring or mutually exclusive alterations. With our computational model, we analyse each association to identify the deregulated pathways and their contribution to tumorigenesis. In some cases (e.g., co-occurrence of FGFR3 and PIK3CA mutations), we found that the sole network topology cannot explain the alteration patterns identified by statistical analysis. It appears necessary to build a dynamical model to accurately and formally identify mechanisms activated in these patterns (25) . When the model cannot straightforwardly account for these patterns, we search for contexts (other activating or inactivating mutations, amplifications or losses) that could explain the statistical results. Mathematical modelling provides insights into properties of involved cellular pathways. It is thus useful to understand mechanisms at play, as a complement to statistical methods, which uncover patterns of alterations. Here, our main goal is to highlight mechanisms 
DNA extraction from tissues
Immediately after surgery, tissue samples were frozen in liquid nitrogen and stored at -80°C until nucleic acid extraction. DNA were extracted from frozen human bladder tissues as described in (26) . 
Gene mutation analysis
FGFR3 mutations were studied with the SNaPshot method (29) . TP53 (exons 2-11), KRAS (exons 2-3), NRAS (exons 2-3), HRAS (exons 2-3) and PIK3CA (exons 2, 9 and 20) gene mutations were screened by direct sequencing with previously described primers and protocols (30, 31) , available on request. All mutations were confirmed by sequencing both strands of a second, independent PCR product.
CGH array analysis
DNA copy number was analysed for the 178 bladder tumours on the human genomewide CIT-CGH array (V6) designed by the CIT-CGH Consortium. This array contains 4,434 sequence-verified bacterial artificial chromosome (BAC) and P1-derived artificial chromosome (PAC) clones. Genomic alterations were determined using GLAD algorithm (32) .
Multiplex ligation-dependent probe amplifications (MLPA) analysis
DNA copy number at the CDKN2A and RB1 loci was determined using a MLPA assay, as described in (33) . Bladder tumour DNA was analysed with the P024B kit and P047 kits (MRC-Holland, Amsterdam, the Netherlands) for genomic analysis of CDKN2A/B and RB1, respectively. Two of the 14 control probes spanning chromosomal regions 9q21 and 11p12 were excluded from the RB1 copy number analysis because these regions are frequently altered in bladder tumours. Table 1 reports p-values of the Fisher exact tests for all pairs of selected genetic alterations. For each alteration, we split the tumour samples into two groups with and without the alteration, and analysed the corresponding contingency tables for pairs of alterations. The significance threshold was set to 5%. We performed the tests using R software. Figure 1 depicts the workflow designed for this study. We first searched the literature on published co-occurrence and mutual exclusivity patterns, focusing on genetic alterations (mutations, homozygous losses, and amplifications) of genes known to be frequently altered in bladder cancer and reported in previous studies (37, 38) . These genes code mainly for proteins involved in growth factor receptor signalling (EGFR, Table S9 ). We finally verified the patterns deduced from both the literature search and the statistical analysis in three additional independent bladder tumour datasets (referred to as Lindgren dataset (37), Iyer dataset (38), and TCGA dataset (39)).
Testing mutual exclusivity and co-occurrence of genetic alterations
A model including the selected genes was built using molecular facts extracted from scientific publications. It was validated against published phenotypes of mice mutants (Table S3) . Both the topological analysis of the network and the mathematical model were used to explain the patterns of alterations, formulate predictions such as expected effect of genetic contexts or yet probe results from the data analysis. When possible, model predictions were verified in the datasets.
Data analysis of patterns of co-occurrence and mutual exclusivity
The identified associations concern: FGFR3, RAS, PIK3CA, CCND1, E2F3
(oncogenes) and RB1, TP53, CDKN2A (tumour suppressors). We organised these associations into 4 groups ( (41)).
On CIT dataset, we performed the Fisher's exact test of independence for each pair of alterations (Table 1 ; columns 3 to 5). Because some associations depend on the stage, we considered all tumours and separately: non-muscle-invasive (sup) and muscleinvasive tumours (inv). Note that stratifying tumours by both stage and grade would have resulted in subgroups too small to achieve statistically significant tests. We found associations not previously reported in the literature for bladder cancer: exclusivity of FGFR3 mutations and E2F3 amplifications ( 
Proceeding with our workflow, we mined three publicly available datasets, searching for associations found in the literature and/or in our CIT dataset. We considered each dataset separately (Table 1 ; columns 6-10), as well as an ensemble gathering all muscle-invasive datasets (Lindgren, Iyer and TCGA muscle-invasive tumours, Table   1 ; column 11). Non-muscle-invasive tumours, besides CIT dataset, are only found in Lindgren dataset. Among the published associations, all were confirmed in at least one of the four datasets, except for the last one: co-occurrence of E2F3 amplifications and RB1 deletions was not found significant in any dataset (not shown). We thus chose not to further study it. Eight out of these nine remaining patterns were verified in at least one of the three public datasets, among which two were slightly above the 5% threshold (Table 1 ; rows 1.1 & 4.1). Figure 3 recapitulates these associations.
Computational network modelling From the influence network to the logical model
Based on an extensive literature search and on our previous work (44), we built a generic simplified influence network around E2F activating transcription factors in response to cell receptor activation (EGFR and FGFR3), growth inhibition (mainly representing TGFβ) and DNA damage, yet focusing on genes altered in bladder cancer. We considered the major players involved in both RB/E2F and TP53 pathways, controlled by the same transcription factor, E2F1, which included the genes identified in the data analysis.
The network of Figure 4 summarizes information from the literature and from pathway databases, such as Reactome (45) Readouts for these phenotypes are: presence of CyclinE1 (CCNE1) or CyclinA (CCNA2) for proliferation, of TP53 for E2F1-independent apoptosis, of E2F1 for E2F1-dependent apoptosis, and of p21CIP (CDKN1A), RBL2 or RB1 for growth arrest. These molecular readouts are considered as phenotype triggers, possibly followed by downstream events, not described here. For example, when either CyclinE1 or CyclinA is active, it indicates that the cell enters S phase. Similarly, TP53 activation does not necessarily lead to apoptosis but rather triggers it (Supp. Quick Guide to Equations and Assumptions) are described in Table S1 . The model has 20 stable states and 5 cyclic attractors (Table S2) To test the model coherence, we challenged it with published experiments on diverse cell types (mouse embryo and rat fibroblasts, murine retina, etc.) by targeting the corresponding network nodes, and checking that our model qualitatively reproduces mutant phenotypes (Table S3) .
Data interpretation using the model
In the light of the model properties, we verified the possible cooperating or exclusive mechanisms corresponding to associations. To support our findings, for each association, we considered the corresponding mutants and quantified the related phenotypes (Material and Methods, Table 1 and Figure S1 ).
Mutual exclusivity between FGFR3
and RAS mutations is confirmed by our model. As shown in the network (Figure 4 ), FGFR3 is upstream of RAS (in our model, FGFR3 directly activates RAS). Hence, for FGFR3 overexpressed mutant, RAS is active in all stable states and, consequently, additional mutations of RAS do not alter these phenotypes; there is no advantage for the tumour to mutate RAS when FGFR3 is already mutated. Note that single RAS overexpressed mutant has a higher probability of Proliferation phenotype, which can also be reached through EGFR signalling (Tables 2, Figure S1 ). In the case of single FGFR3 mutant, EGFR is always OFF (due to mutual inhibition of FGFR3 and EGFR through PKC (12) 
Indeed, the model shows that E2F3 is activated when FGFR3 activity is forced and simulations confirm that there is no advantage for the cancerous cell to amplify E2F3
if FGFR3 is already mutated (Table 2, Figure S1 ). Proliferation probability slightly decreases in the double mutant compared to single E2F3 overexpressed mutant for reasons similar to those evoked for the previous association.
Mutual exclusivity of FGFR3 mutations and CCND1 amplifications is suggested
in CIT superficial tumours but has not been reported so far in the literature, and is not confirmed in other datasets. Our model shows an increase in proliferation when further amplifying CCND1 in an FGFR3-mutated tumour (Table 2, Figure S1 ), thus contradicting the exclusivity observed in our CIT data but in agreement with absence of this pattern in other datasets. CCND1 can be activated by FGFR3, but may have additional beneficial roles for the tumour, not explained by the model straightforwardly (dashed line in Figure 3) . Indeed, we find that in the single FGFR3 mutant (with DNA damage ON), the apoptotic phenotype is TP53-dependent whereas Figure S1 ). We would expect PI3K activating mutations to favour uncontrolled growth in an FGFR3-mutated context by promoting survival and blocking apoptosis. However, our model shows that it is not the case: to fully lead to uncontrolled proliferation, other checkpoints need to be deleted, e.g. CDKN2A. The systematic analysis of multiple mutants predicts that indeed, a third deletion of CDKN2A (equivalent to p16INK4a KO in our simulations) (Tables S4-S7) . We verified this observation in the data, but unfortunately, there are too few samples with the three alterations to perform significant statistical tests; however, among the 12 samples that carry the double mutations FGFR3 and PIK3CA, the two samples that are muscleinvasive have lost the two copies of CDKN2A. (Table 2 and Figure S1 ), hence no clear advantage for co-occurrence of these two alterations. As mentioned above, mutations of PIK3CA, but also deletions of CDKN1A (p21CIP) would drastically favour proliferation (Tables S4 and S8 ). Recall that RB/E2F pathway is not only involved in proliferation but also in invasion and metastasis (22) (23) (24) ; thus, we anticipate that highly proliferative tumours are invasive ( Figure S2 shows that expression of gene targets of the E2F1-3 transcription factors is correlated to tumour stages). p21CIP seems to be a good candidate for progression towards invasiveness. This is supported by the reported association of p21CIP with poor clinical outcome in urothelial bladder cancer (47) . Unfortunately, there are two few samples to achieve 
statistical significance for p21CIP alterations in CIT or TCGA datasets, even though among the five tumours that are both FGFR3-mutated and p21CIP-altered in TCGA (i.e., mutated or deleted), four are CDKN2A homozygously deleted.
The model also suggests that the double mutant EGFR overexpressed and CDKN2A deleted (equivalent to EGFR amplifications and CDKN2A homozygous loss) gives similar results as the triple mutant FGFR3-mutated, PIK3CA-mutated, and CDKN2A deletion: only Proliferation phenotypes are reached in absence of DNA damage. In the CIT dataset, EGFR amplified tumours (which belong to the basal-like bladder tumour subtype (48)) do not seem to lose CDKN2A more frequently than FGFR3-mutated tumours, and, more surprisingly, CDKN2A expression is increased when compared to the non-basal tumours. This suggests two things: (1) CDKN2A may compensate transcriptionally for the loss of RB activation in these tumours; and (2) in bladder, FGFR3 activates the cell cycle through CDK4/6 (CDKN2A-dependent), whereas EGFR activates the cell cycle in a CDKN2A-independent manner. In agreement with this idea, CCNB1 and CCNE2, whose actions are CDKN2A-independent, are both overexpressed in basal-like bladder tumours presenting an activation of EGFR target genes (48) .
Mutual exclusivity of FGFR3 and TP53 mutations has been reported for all tumours rather than tumours separated by stage (19) . In our model, when TP53 is mutated, Apoptosis is still reachable through E2F1, whereas Apoptosis is only TP53- CAN-15-0602 mutated, it is advantageous to mutate any gene from the cell cycle machinery (here FGFR3, but amplification of any oncogene from our network would serve, as shown in the next association). From these results, we can only conclude that mutual exclusivity may concern FGFR3-mutated tumours.
We anticipate that EGFR amplifications and mutations of TP53 would be associated in muscle-invasive tumours. In the data, the amplifications for EGFR are rare (4 in CIT, 1 in Lindgren, 0 in Iyer, 10 in TCGA). But, recently, a subgroup of tumours was identified with overexpression of EGFR (either through transcriptional mechanisms or amplification) and indeed enriched with TP53 mutations (48).
Co-occurrence of TP53 mutations and E2F3 amplifications has not been reported but appears significant in CIT data. The model shows an increase in proliferation when comparing TP53 single mutant with the double mutant TP53-deleted E2F3-overexpressed, which is not the case when comparing E2F3 single mutant with the double mutant (Table 2, Figure S1 ). In other words, this co-occurrence is beneficial for the tumour cell when mutations of TP53 appear first. We looked more closely at CIT dataset: there are 58 TP53-mutated and 11 E2F3-amplified samples in total. We found that among the 11 E2F3-amplified tumours, 9 are TP53-mutated, and 7 out of these 9 are muscle-invasive. In Iyer dataset, 15 out of 20 E2F3-amplified tumours are also TP53-mutated. As mentioned in the previous association, amplifying E2F3 might be one way to favour proliferation when tumours are already TP53-mutated.
Co-occurrence of CCND1 amplifications and CDKN2A homozygous deletions has been reported for head and neck squamous cell carcinomas (42, 43) has already an advantage over deleting CDKN2A (p16INK4a and p14ARF deletions in the model) alone in terms of proliferation (Table 2, Figure S1 ). It is known that CDKN2A inhibits CCND1 by forming a complex with the cyclin-dependent kinases, CDK4 or CDK6. As a consequence, its loss facilitates the activation of CCND1 but does not necessarily promote proliferation. The double mutant shows an increase in proliferation when compared to both single mutants (Table 2, Figure S1 ). Our model thus confirms co-occurrence of these alterations. The role of CDKN2A in senescence is not considered here, and we anticipate that it may play an additional role that we cannot account for in this model.
Co-occurrence of PIK3CA mutations and CDKN2A homozygous deletions is similar to the previous case. The double mutation increases the probability to reach proliferation compared to single mutants. Indeed, the double mutant PI3K overexpressed and CDKN2A deleted (p16INK4a and p14ARF deletions) suppresses the Growth_arrest attractors (Table 2, Figure S1 , Table S6 ).
Discussion
By performing literature search and data mining of four independent bladder cancer datasets, we identified nine patterns of co-occurrence and mutual exclusivity in genetic alterations affecting growth factor signalling pathways, cell cycle and apoptosis. In order to explain the reasons and contexts for these patterns, we defined a mathematical model derived from an influence network encompassing the frequently altered genes (Figure 4) . We simulated the mutants corresponding to the patterns and provided different types of predictions. First, we concluded that, in some cases, co- occurrence needs to be accompanied by a third mutation to be associated with invasiveness, e.g., PIK3CA mutations or p21CIP deletions in an FGFR3-mutated and CDKN2A-deleted context. Next, we found that the order of mutations might explain associations and concluded that some events occur late during tumorigenesis (e.g., co-occurrence of TP53 mutations and E2F3 amplifications).
In some cases, our model suggests that co-occurring genetic alterations prepare a context for more aggressive tumours (e.g., Of course, some predictions remain to be checked in other public datasets, as soon as they are made available (e.g., the role of p21CIP in invasiveness). To draw our conclusions, we considered CGH and sequencing data, but many other events can happen downstream of gene activity. It would be appropriate to include other types of data like mRNA expression, DNA methylation, protein level, etc. We plan to include at least transcriptomic data in future analyses and anticipate that other genes will appear to play a role in the process of invasiveness.
Finally, we analysed association patterns limiting ourselves to cell cycle and apoptosis entries. Some of our explanations may be incomplete because of the involvement of important genes in other cell fates such as senescence (e.g., TP53, CDKN2A, RBL2, etc.) (50). Similarly, PTEN role will need to be further explored in pathways other than PI3K/AKT as reported by (26, 51 
